Assessment of organ dose reduction and secondary cancer risk associated with the use of proton beam therapy and intensity modulated radiation therapy in treatment of neuroblastomas

Table 2 Dose profiles of each organs

		Dose (Gy)			Fraction of cases decrease with respect to CRT (%)
		CRT	IMRT	PBT	IMRT	PBT
Liver	Mean	14.2	13.3	6.3	60	100
	D _5%	32.1	25.3	22.8	100	100
	D_50%	10.0	12.8	3.5	40	100
	D_90%	2.8	4.1	0.2	0	100
Stomach	Mean	20.3	21.5	11.8	60	80
	D _5%	32.9	31.7	20.4	80	100
	D_50%	17.7	20.7	5.0	60	100
	D_90%	10.5	13.5	2.2	40	100
Small intestine	Mean	9.4	11.2	3.4	20	100
	D _5%	31.4	30.6	21.7	60	100
	D_50%	3.7	7.6	1.4	40	100
	D_90%	0.7	1.1	0.0	0	100
Bone	Mean	20.5	21.7	16.9	20	80
	D _5%	32.2	33.0	27.5	0	100
	D_50%	21.8	24.7	7.7	40	100
	D_90%	1.3	4.3	0.1	0	100
Pancreas	Mean	28.2	28.2	21.2	60	80
	D _5%	32.3	33.2	30.6	20	100
	D_50%	31.5	31.1	20.9	60	80
	D_90%	17.0	16.8	11.9	40	80
Colon	Mean	9.9	11.2	2.1	60	100
	D _5%	31.8	26.6	14.0	100	100
	D_50%	8.5	10.4	0.1	20	100
	D_90%	0.7	0.9	0.0	0	100

ISSN: 1748-717X